Measurement of neonatal abstinence syndrome: Evaluation of short forms

Hendrée E. Jones, Carl Seashore, Elisabeth Johnson, Evette Horton, Kevin E. O'Grady, Kim Andringa

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: 1) How well do the short forms previously developed from the Maternal Opioid Treatment: Human Experimental Research (MOTHER) neonatal abstinence syndrome (NAS) scale (MNS) discriminate between neonates untreated and treated for NAS? (2) Can a short form be developed that is superior to other short forms in discriminating between the two groups?

DESIGN/PARTICIPANTS: This secondary analysis study used data from 131 delivered neonates in the MOTHER study, a randomized controlled trial comparing neonatal and maternal outcomes in opioid-dependent pregnant women administered buprenorphine or methadone.

SETTING: Comprehensive care was provided at seven university hospitals.

OUTCOME MEASURES: A 19-item instrument measuring neonatal abstinence signs.

RESULTS: A five-item index proved superior to the previous indices (ps <0.01) and discriminated between the treated and untreated NAS groups as well as did the MNS total score (p=0.09).

CONCLUSIONS: A short form developed from the MNS shows promise as a possible screening measure.

Original languageEnglish (US)
Pages (from-to)19-23
Number of pages5
JournalJournal of Opioid Management
Volume12
Issue number1
DOIs
StatePublished - Jan 1 2016

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Measurement of neonatal abstinence syndrome: Evaluation of short forms'. Together they form a unique fingerprint.

  • Cite this

    Jones, H. E., Seashore, C., Johnson, E., Horton, E., O'Grady, K. E., & Andringa, K. (2016). Measurement of neonatal abstinence syndrome: Evaluation of short forms. Journal of Opioid Management, 12(1), 19-23. https://doi.org/10.5055/jom.2016.0308